No, because (as vinmantoo noted), MNTA has not sold any product in violation of Teva’s Copaxone patents. Still, the lawsuit has incurred implicit damages insofar as MNTA has had to pay a portion of the legal expenses.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”